Letermovir Improves Real-World, 5-Year Overall Survival Among CMV Seropositive Allogeneic Hematopoietic Cell Transplant Recipients (TCT-ASTCT-CIBMTR 2026) - Jan 8, 2026 - Abstract #885; 448; Pres time: Feb 5, 2026; 06:30 PM - 08:00 PM; Location: Hall AB (Salt Palace Convention Center); "3. Compare overall survival rates between CMV-seropositive subjects treated with letermovir and CMV- seronegative subjects who did not receive letermovir."
Clinical • Real-world • Real-world evidence • Bone Marrow Transplantation • Cytomegalovirus Infection • Infectious Disease • Transplantation
|
|
Morgan Bizzell, PharmD, BCOP 1,2; Daniel J Crona, PharmD, PhD 3,4,5; Hailey Hirata, PharmD, BCOP 2,6; Jonathan Ptachcinski, PharmD, BCOP, BCPS, CPP 1,2; Morgan Trepte, PharmD, CPP 1,2; Tatjana Grgic, PharmD, BCOP, CPP 1,2,7; Anson Snow, MD 1,5,8; Paul M. Armistead, MD, PhD 1,5,8; Tessa Andermann, MD, MPH 5,9; Ryan Shaw, PharmD, BCPS, BCOP, CPP 1,2,7
|